Biotech

All Articles

Despite combined market, a financial backing resurgence might be coming in Europe: PitchBook

.While the biotech financial investment scene in Europe has slowed down relatively observing a COVID...

8 months after a $213M fundraise, genetics publisher Tome helps make cuts

.After bring up $213 million in 2023-- some of the year's most extensive personal biotech shots-- To...

BioMarin creates exec crew with biotech vets-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of notable leadership hirings, firings and al...

Biopharma Q2 VC reached highest level since '22, while M&ampA slowed

.Financial backing backing right into biopharma cheered $9.2 billion throughout 215 deals in the 2nd...

Bicara, Zenas find IPOs to drive late-phase assets towards market

.Bicara Therapies and also Zenas Biopharma have actually offered fresh incentive to the IPO market w...

Genentech to shut cancer cells immunology study team

.Genentech will shut its own cancer immunology research department, and unit mind as well as well-kn...

Kezar loses strong lump however to show its own really worth in period 1 test

.Kezar Life Sciences is actually losing its own dim period 1 strong cyst medicine as the biotech goe...

Acelyrin drops izokibep, dismisses 3rd of personnel

.Regardless of izokibep sustaining its own newly found winning touch in the clinic, Acelyrin is no l...

Rivus' period 2 obesity-related heart failure trial hits endpoint

.Rivus Pharmaceuticals has actually plumped up the customers of its own fat-busting, muscle-sparing ...

Ovid stops preclinical work, IV course after soticlestat stop working

.Ovid Therapeutics actually revealed last month that it was actually trimming back its head count as...